Rösch W
Department of Medicine, Northwest Hospital, Frankfurt/Main, F.R.G.
Scand J Gastroenterol Suppl. 1989;165:54-8. doi: 10.3109/00365528909091231.
Non-ulcer dyspepsia is gaining increasing interest among gastroenterologists even though the pathogenetic mechanisms in individual patients are still unknown. On the basis of a number of studies, it can be concluded that in about 60% of patients impairment of gastric evacuation may contribute to the symptomatology (epigastric pain, postprandial fullness, early satiety, bloating, nausea and vomiting). This review summarizes the results of 10 placebo-controlled trials which evaluated the effects of cisapride (3 x 5 or 3 x 10 mg/day) in strict non-ulcer dyspepsia or functional postprandial dyspepsia. In seven of the trials, cisapride proved significantly superior to placebo in relieving epigastric pain and concomitant symptoms in patients with non-ulcer dyspepsia. In the three studies examining chronic functional dyspepsia, belching, postprandial bloating, early satiety and heartburn were significantly improved. In all 10 trials, cisapride was significantly superior to placebo.
尽管个体患者的发病机制仍不清楚,但非溃疡性消化不良越来越受到胃肠病学家的关注。基于多项研究,可以得出结论,约60%的患者胃排空受损可能导致症状(上腹部疼痛、餐后饱胀、早饱、腹胀、恶心和呕吐)。本综述总结了10项安慰剂对照试验的结果,这些试验评估了西沙必利(3×5或3×10mg/天)对严格的非溃疡性消化不良或功能性餐后消化不良的疗效。在7项试验中,西沙必利在缓解非溃疡性消化不良患者的上腹部疼痛及伴随症状方面明显优于安慰剂。在3项研究慢性功能性消化不良的试验中,嗳气、餐后腹胀、早饱和烧心症状得到明显改善。在所有10项试验中,西沙必利均明显优于安慰剂。